

jc525
02/02/99
U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Certification under 37 CFR §1.10 (if applicable)

EM 416 978 988 US
Express Mail Label Number

February 2, 1999
Date of Deposit

UC525 PTO
02/02/99

I hereby certify that this Transmittal Letter, enclosed application and any other documents referred to as enclosed herein, are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Jennifer Mahoney
(Print Name of Person Mailing Application)


(Signature of Person Mailing Application)

UC525 PTO
02/02/99

Transmittal of Utility Patent Application
for Filing Under 37 CFR §1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is a utility patent application by inventors: Jörg Reimann and Yechezkel Barenholz and entitled:

Delivery of Immunogenic Molecules via HbsAg Particles

1. Enclosed are:
 - This Transmittal letter.
 - One stamped, self-addressed postcard for PTO date stamp.
 - Certificate of Express Mail.
 - One utility patent application containing text pages 1-15 and 6 Sheets of drawings.
 - Declaration of inventorship (unsigned)
 - Assignment(s) for recordation with transmittal sheet.
 - Small Entity Statement(s).
 - Executed Power of Attorney by Assignee
 - Sequence listing printout, diskette, matching declaration.
2. U.S. Priority
 - This application claims priority to U.S. provisional application Serial No. 60/073,476 filed February 3, 1998.
 - A petition for extension of time has been filed in the parent to extend the pendency of the parent to _____ (copy enclosed).
 - Conditional Petition for Extension of Time: An Extension of Time is requested to provide for timely filing if required to establish copendency with the parent after all papers filed herewith have been considered.

3. Foreign Priority

- Priority of Application No. _____ filed in _____ on _____ is claimed under 35 USC §119.
- A certified copy of this priority document is enclosed.

4. Fees

The filing fee has been calculated as shown below:

For:	(Col. 1) No. Filed	(Col. 2) No. Extra	Small Entity		Other Than a Small Entity	
			Rate	Fee	Rate	Fee
Basic Fee				\$380.00	or	\$760.00
Total Claims	30 - 20	10	x \$ 9 =	\$ 90.00	or	x \$ 18 =
Independent Claims	4 - 3	1	x \$39 =	\$ 39.00	or	x \$ 78 =
<input type="checkbox"/> Multiple Dependent Claim Presented			+ \$130 =	\$	or	+ \$260 =
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.			TOTAL	\$	or	TOTAL

- A check for \$ _____ is enclosed to cover the Filing Fee.
- Please charge Deposit Account 04-0531 in the amount of \$ _____.
- The Commissioner is hereby authorized to charge fees under 37 CFR §1.16 and §1.17 which may be required, or credit any overpayment to Deposit Account 04-0531.
- Filing fee to be submitted in response to anticipated receipt of Notice to File Missing Parts of Application. DO NOT CHARGE DEPOSIT ACCOUNT.

Respectfully submitted,


LeeAnn Gorthey
Registration No. 37,337

Date: 2-2-99

Correspondence Address:

Dehlinger & Associates
P.O. Box 60850
Palo Alto, CA 94306
(650) 324-0880

Transmittal of Utility Patent Application for Filing*Certification Under 37 C.F.R. §1.10 (if applicable)*EM 416 978 988 US

"Express Mail" Label Number


February 2, 1999

Date of Deposit

I hereby certify that this Transmittal letter, enclosed application, and any other documents referred to as enclosed herein are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Jennifer Mahoney

(Print Name of Person Mailing Application)



(Signature of Person Mailing Application)

Delivery of Immunogenic Molecules via HBsAg Particles

- 5 The present application claims priority to U.S. provisional application 60/073,476, filed February 3, 1998, which is hereby incorporated by reference.

Field of the Invention

- The present invention relates to compositions in which a biologically active molecule, such as
10 an antigenic peptide, a cytokine, or an oligonucleotide, is contained in an HBsAg particle, and to therapeutic uses of such compositions, particularly for enhancing the immunogenic activities of the components.

References

- 15 Aspinall, G.O. *et al.*, *Adv. Carbohydr. Chem. Biochem.* **51**:169-242 (1995).
Clarke, B.E. *et al.*, *Nature* **330**(26):381-4 (1987).
Delpyroux, F. *et al.*, *Science* **233**:472-81 (1986).
Diminsky, D. *et al.*, *Vaccine* **15**(6/7):637-647 (1997).
Felgner, P.L. *et al.*, *Biochemistry* **20**(8):2168-2172 (1981).
20 Francis, M.J. *et al.*, *Proc. Natl. Acad. Sci. USA* **87**:2545-9 (1990).
Geissler, M. *et al.*, *J. Immunol.* **158**(3):1231-7 (1997).
Lowry, O.H. *et al.*, *J. Biol. Chem.* **193**:265-275 (1951).
Nguyen, T.D. *et al.*, *Cancer. Immunol. Immunother.* **43**(6):345-54 (1997).
Perin, F. *et al.*, *Nucl. Med. Biol.* **21**(8):1093-100 (1994).
25 Puzo, G., *Crit. Rev. Microbiol.* **17**(4):305-27 (1990).
Schirmbeck, R. *et al.*, *J. Immunol.* **152**(3):1110-1119 (1994).

- Talmon, Y., *Ber. Bunsenges. Phys. Chem.* **100**(3):364-72 (1996).
- Weiner, G.J. et al., *Proc. Natl. Acad. Sci. USA* **94**(20):10833-7 (1997).
- Wong, M. et al., *Biochemistry* **23**:6498-6505 (1984).
- Wooldridge, J.E. et al., *Blood* **89**(8):2994-8 (1997).
- 5 Yachi, K. et al., *J. Microencapsul.* **12**(4):377-88 (1995).
- Yamamoto, S. et al., *J. Immunol.* **148**(12):4072-6 (1992).
- Yamamoto, T. et al., *Antisense Res. Dev.* **4**(2):119-22 (1994).

Background of the Invention

10 Conventional vaccines against infectious viruses or microorganisms frequently employ inactivated or live-attenuated pathogen. Disadvantages of such vaccine preparations include difficulty in large-scale production, safety considerations in handling, and the risks involved in immunizing elderly or immunodeficient individuals with live-attenuated vaccines.

Subunit vaccines, which utilize isolated components of a virus particle, are a safer alternative

15 to conventional vaccines. The components are typically recombinant proteins or synthetic short peptides. However, most subunit vaccines, like most soluble antigens, generally elicit only a humoral immune response, which stimulates B-lymphocytes to produce antibodies. Such a response is effective in attacking bacteria and viruses in the extracellular media, but not in the elimination of intracellular bacteria, parasites and virus-infected cells. For maximum

20 effectiveness, a vaccine should also be able to elicit a CTL (cytotoxic T-lymphocyte) response. The CTL response stimulates the production of "killer" T-lymphocytes, which attack cells perceived as abnormal, including virus-infected cells.

The mode of processing and presentation of an antigen determines which T cell subtype (helper or cytotoxic) is activated during the immune response. In the exogenous (Class II) pathway, exogenous antigens enter an antigen presenting cell (APC) via endocytosis or a related mechanism. The proteins then undergo proteolysis, yielding peptides having 10-20 amino acids, which bind to MHC-II molecules. The resulting complexes stimulate CD4+ (helper) T cells, which regulate humoral immune responses. In the endogenous (Class I) pathway, proteins present in the cytoplasm, such as viral proteins, are degraded to peptides 8-10 amino acids in length,

25 which bind to MHC-I molecules. The resulting complexes interact with CD8+ (cytotoxic) T-lymphocytes (CTL). As noted above, this response is especially important for protection against virus-infected cells or intracellular microorganisms.

Accordingly, it is desirable to provide immunogenic compositions which produce an effective CTL immune response, particularly for use with soluble antigens.

Summary of the Invention

The present invention includes, in one aspect, a method of stimulating, enhancing or modulating an immune response to an antigen in a mammalian subject, by administration of an effective amount of a composition of the antigen contained in an HBsAg particle. In a preferred embodiment, the immune response is a CTL response, and is enhanced, preferably by a factor of two or more, relative to that elicited by the molecules when administered without HBsAg. The subject compositions are also effective to produce a CTL response when the antigenic molecule, administered without HBsAg, is substantially ineffective in producing such a response.

The HBsAg particle is preferably a recombinant particle, either yeast-derived or produced in a mammalian cell, such as a CHO (Chinese hamster ovary) cell. The encapsulated molecule is preferably an antigenic protein or peptide. Specific embodiments include those in which the molecule is ovalbumin or HIVenv/V3 peptide. In additional embodiments, the composition further includes an immunostimulating molecule, such as a cytokine or immunostimulating oligonucleotide, contained in the HBsAg particle.

In another aspect, the invention provides a method of stimulating, enhancing or modulating an immune response to HBsAg in a mammalian subject, by administration of an effective amount of a composition of an immunostimulating molecule contained in an HBsAg particle. In a preferred embodiment, the immune response is a CTL response, and the subject is a nonresponder at the CTL level when administered HBsAg particles without the immunostimulating molecule.

Preferably, the immunostimulating molecule is a cytokine, such as IL-12, IL-10, or IFN- γ ; IL-12 and IFN- γ are particularly preferred. Other immunostimulating molecules include cholera toxin (CT) protein, staphylococcal enterotoxin B (SEB) protein, and immunostimulating oligonucleotides.

Also provided is an immunogenic composition, comprising an HBsAg particle, and contained therein, a biologically active molecule. The composition is preferably prepared by incubating the particles in an aqueous medium in the presence of the molecule. In a preferred embodiment, the molecule is an antigen, e.g. HIVenv/K^d peptide. In other preferred embodiments, the molecule is an immunostimulating compound, or the particle may contain both an antigen and an immunostimulating molecule. Preferred immunostimulants include a cytokines, such as IL-10, IL-12 or IFN- γ , and immunostimulating oligonucleotides. Other immunostimulating molecules which may be used include cholera toxin (CT) protein and staphylococcal enterotoxin B (SEB) protein.

The composition may also include a glycolipid incorporated into the external face of the lipid bilayer of the HBsAg particle, where the glycolipid preferably includes at least one mannose residue.

The invention also provides, in another aspect, a method of incorporating a biologically active molecule into an HBsAg particle. According to the method, the particles are incubated in an aqueous medium in the presence of the molecule. The temperature of incubation is preferably between about 35°C and about 60°C, and more preferably between about 55°C and about 60°C.

- 5 The method may also include incorporating a glycolipid into the exterior surface of the HBsAg particle, preferably co-incubating the glycolipid with the HBsAg particles and biologically active molecule.

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying
10 drawings.

Brief Description of the Drawings

Figure 1 shows a computer generated image of a cryotransmission electron micrograph of an HBsAg particle, showing the structure of the porous lipid vesicle having defined protein pores;

- 15 Figure 2 is a topographical image of an HBsAg obtained from image analysis of a cryotransmission electron micrograph of the particle;

Figure 3 shows the ratio of total protein area to area of 24kd+27kd proteins, as determined by gel electrophoresis, of HBsAg alone and HBsAg incubated with ovalbumin at a series of increasing temperatures;

- 20 Figure 4A shows the level of anti-HBsAg CTL response induced by cells stimulated with HBsAg alone, with OVA alone, and with OVA encapsulated in HBsAg, against HBsAg-specific cells (P815/S) and nonspecific cells (P815);

Figure 4B shows the level of anti-OVA CTL response induced by cells stimulated as for Fig. 4A, against OVA-specific cells (EG7) and nonspecific cells (EL4);

- 25 Figure 4C shows the level of anti-HBsAg antibody response induced by HBsAg alone, OVA alone, and OVA encapsulated in HBsAg;

Figure 4D shows the level of anti-OVA antibody response induced by the compositions shown for Fig. 4C;

- 30 Figure 5A shows the level of anti-HBsAg CTL response induced by cells stimulated with HBsAg alone, with HIV envV3-peptide alone, and with HIV envV3-peptide encapsulated in HBsAg, against HBsAg-specific cells (P815/S) and nonspecific cells (P815);

Figure 5B shows the level of anti-HIV envV3-peptide CTL response induced by cells stimulated as for Fig. 5A, against HIV envV3-peptide-specific cells (P815/HIV envV3-peptide) and nonspecific cells (P815); and

Figures 6A-H show the level of anti-HBsAg CTL response induced in cells of 'nonresponder' mice (C57BL/6 H2-b) by HBsAg alone (A), HBsAg containing various cytokines (B-F), and IL-12 alone (G), and by HBsAg/IL-12 in a control experiment (H) in which the effector cells were restimulated with non-antigen-bearing cells.

5

Detailed Description of the Invention

I. Hepatitis B Surface Antigen (HBsAg)

A. Background

Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis in humans. During 10 HBV replication, a large excess (1000:1) of "empty" surface particles, containing neither capsids nor viral DNA/RNA, are produced. These HBsAg (hepatitis B surface antigen) particles are potent immunogens in humans and many animal species.

First generation HBV subunit vaccines included HBsAg particles purified from the plasma of 15 human chronic carriers. Due to the limited supply of carrier plasma and major safety problems, vaccines based on recombinant HBsAg particles derived from yeast (*Saccharomyces cerevisiae*) were introduced. More recently, a third generation recombinant HBV vaccine, which better resembles the human-derived particles, was introduced. These HBsAg particles are derived from Chinese hamster ovary (CHO) cells in culture and are referred to herein as CHO-HBsAg particles.

20 B. Structure

The composition, structure and immunogenicity of yeast- and CHO-derived HBsAg particles have been described (Diminsky *et al.*). The particles are about 20-33 nm in size and are composed of about 60% protein and 40% lipid by weight. Phospholipids are the predominant lipids. The CHO-derived particle differs primarily from the yeast-derived particle in that it 25 includes three HBsAg surface proteins (each in two forms of glycosylation), designated large (L), medium (M) and small (S), while the latter includes only the nonglycosylated S peptide.

Biochemical analysis revealed that almost all (approx. 85%) HBsAg particle phospholipids are hydrolyzed by phospholipases A2 and C, and all aminophospholipids react with trinitrobenzene sulfonate (Diminsky). These observations suggested that the particle is not a sealed vesicle, but 30 rather exists in the form of (a) a lipoprotein, having a monolayer of polar lipids coating a core of neutral lipids and part of the protein, or (b) a porous vesicle whose pores are permeable to the above reagents. Cryotransmission electron microscopy (Figure 1) confirmed the latter possibility, showing, at a resolution of 1 nm, a porous vesicle.

Phospholipids cover large areas of the outer and inner protein component of the particle, but

some protein domains loop out of the lipid layer and are accessible to antibodies or proteases. The particles are hollow, encapsulating a space of about 900 - 8200 cubic nm per particle. Access to the interior of the particles is mediated by the pores, which have an average diameter of about 1-2 nm.

5 Figures 2A and 2B show topographical images of HBsAg particles, each about 22 nm in diameter, obtained by image analysis of cryotransmission electron micrographs of the particles. (For a review of TEM methods see Talmon, 1996.) Such image analysis can be carried out using software provided by NIH or Adobe Systems Inc. Regions of higher density in the image were assigned higher values along the vertical (out of plane) axis, as shown in Figures 2A-2B. As
10 represented in the Figures, the center of each vesicle contains an aqueous phase (lighter regions, having small numeric values). Proteins (darkest regions, having highest numeric values) are embedded in the lipid bilayer (medium tone regions). Pores in the bilayer can be clearly seen, as indicated by arrows in the Figures.

15 **II. Encapsulation of Antigens in HBsAg Particles**

In accordance with the present invention, it has been found that biologically active molecules, such as antigenic proteins and peptides, oligonucleotides, or cytokines, may be encapsulated in the hollow HBsAg particles, by virtue of the pores described above. As used herein, the terms "encapsulated in" or "contained in" indicate a physical containment or entrapment of the
20 molecules, rather than a covalent linkage, as is found in fusion proteins, discussed further below. This containment refers both to molecule encapsulated within the interior of an HBsAg particle and to entrapped molecule which is exposed or present at the surface of the particle, by virtue of its porous structure.

The resulting compositions produce enhanced immune responses to the encapsulated antigenic
25 molecules. In particular, the present compositions can stimulate a CTL response, which is enhanced, up to factors of five, ten or more, relative to that elicited by the antigenic molecules when administered without HBsAg. Such enhancement can be evaluated, for example, by percent lysis of specific cells relative to nonspecific control cells, using standard assays, as described below. The subject compositions can be effective to produce a CTL response even when the
30 molecule, without HBsAg, is substantially ineffective in producing such a response (i.e., little or no CTL response is noted in target cells relative to control cells). As described below in Section III, encapsulation of immunostimulating molecules, such as cytokines, in HBsAg particles greatly enhances the immunogenicity of the HBsAg particles themselves.

These effects are demonstrated, in the experiments described below, for a protein having

several hundred amino acids (ovalbumin), a small antigenic peptide (HIV/V3, the third variable domain of the HIV gp120 envelope protein), and several immunostimulants (cytokines).

These examples are not intended to be limiting, and the invention includes HBsAg compositions incorporating other biologically active molecules. Particularly useful, as demonstrated herein, are compositions incorporating antigens or immunostimulating compounds, for the purpose of eliciting an enhanced humoral and cellular immune response. Specific examples of molecules useful in the compositions and methods of the invention include cytokines such as IL-6, IL-7, IL-10, IL-12, IL-15, IL-18, GM-CSF, and IFN- γ , immunostimulating oligonucleotides, genetically modified toxin molecules of tetanus, diphtheria, pertussis, and enterobacteria, malaria CS protein, HIV reverse transcriptase, nucleoprotein and matrix proteins of many viruses, and oncogenic viral proteins.

It is important to distinguish the present compositions, which comprise molecules encapsulated in HBsAg particles, from HBsAg-antigen fusion peptides described previously (e.g. Clarke *et al.*, Francis *et al.*, and Delpeyroux *et al.*). Such compositions are prepared by covalently linking the peptides, or, more typically, via chimeric DNA constructs. The latter approach requires preparing a chimeric DNA containing genes expressing the antigen and the desired HBV protein(s), introducing the fused construct into an appropriate expression vehicle, expressing the fusion protein, and isolating the protein. Delpeyroux *et al.* reported that titers obtained by immunizing mice with HBsAg-polio fusion protein were "low by poliovirus standards." A loss of the immune response against native HB was also observed, probably resulting from distortion of the HBsAg epitopes in the fusion protein. Clarke *et al.* reported significant anti-FMDV (foot and mouth disease virus) titers for an FMDV-HBsAg fusion protein but did not report a CTL response.

The present compositions, in contrast, are prepared by simple incubation of the components, not involving covalent modification. They were found to stimulate significant antibody and CTL responses, as detailed below.

A. Encapsulation of OVA (Ovalbumin) in HBsAg

HBsAg particles were incubated in the presence of OVA protein (100 μ g each in 100 μ l H₂O) at 4°C (on ice), 37°C and 56°C. At the end of 10 min., samples were cooled to 4°C, and the particles were isolated by ultrafiltration. In control experiments, OVA was incubated under identical conditions in PBS buffer, with no HBsAg particles present, and HBsAg particles were incubated under identical conditions without OVA. The OVA/HBsAg collected after ultrafiltration was analyzed by gel electrophoresis, and the protein in each band was quantified

(Diminsky, Lowry). Because OVA overlaps with the PRE S1 (large protein) band of HBsAg, both having a MW of approximately 42kD, analysis was done by comparing total density (39kD + 42kD + 45kD) to that of the two S peptides (24kD + 27kD).

As shown in Fig. 3, the density ratio, and thus the presence of OVA, increased with
 5 increasing temperature of incubation. This effect could be due to an effective expansion, or increased flexibility, of the pores on the surface of the particles with increasing temperature. Quantitative analysis revealed about 6% OVA encapsulation at 56°C. Incubation temperatures much in excess of this, e.g. approaching 80°C, should be avoided, as the compositions are unstable at these temperatures.

10

B1. Induction of a CTL Response to Molecules Encapsulated in HBsAg Particles: OVA

OVA/HBsAg particles, prepared as described above, were isolated, washed, and adjusted to the appropriate concentration for immunization. The following compositions were injected into F1 (H-2d/b) mice, each in 50 µl PBS (phosphate buffered saline): (a) 1 µg HBsAg particles (without adjuvants); (b) 100 µg native OVA; and (c) 1 µg HBsAg/OVA, as described in Section A above.

Figures 4A and 4B show the humoral (serum antibody) response and CTL response, respectively, elicited by each of these compositions, against HBsAg and against OVA. For evaluation of the CTL response, spleen or lymph nodes cells, obtained from immunized mice seven days to five weeks post-vaccination, were specifically restimulated *in vitro* for five days with
 20 syngeneic, irradiated OVA- or HBsAg-peptide-pulsed tumor cells. (The latter cells had been incubated *in vitro* with the recombinant HBsAg particles for 2 hours at 37°C.) The cells were harvested and tested in a 4-hour ⁵¹Cr release cytolytic assay against antigen-bearing and non-antigen-bearing syngeneic targets. Lysis of cells specific for the HBsAg S protein (P815/S), or for OVA (EG7), was compared to that for nonspecific cells (P815 or EL4, respectively). The EG7
 25 cells are EL4 cells which have been stably transfected with an expression plasmid encoding OVA.

As shown in the figures, composition (a), HBsAg alone, evoked both a CTL response and a humoral response against HBsAg. OVA alone elicited a humoral response but no CTL response.

HBsAg-encapsulated OVA, composition (c), elicited a strong anti-HBsAg humoral and CTL response and a weak anti-OVA humoral response. Most significantly, the composition also
 30 elicited a strong anti-OVA CTL response, where none was seen with OVA alone.

B2. Induction of CTL Response to HBsAg-Encapsulated Molecules: HIVenv/V3 Peptide

In a similar set of experiments, BALB/c (H-2d) mice were immunized with the following compositions: (a) 1 µg HBsAg particles (without adjuvants); (b) 100 µg antigenic HIVenv/V3

peptide; and (c) 1 µg HBsAg containing antigenic HIVenv/V3 peptide. This composition was formed by co-incubation of the components, generally as described for OVA, above. It was estimated that approximately 20 ng peptide was incorporated per µg of HBsAg particles.

The CTL response was measured in specific cells (P815/S, as described above, for HBsAg,
5 and P815/V3-peptide for HIVenv/V3 peptide) vs. that in nonspecific P815 cells. The results are shown in Figure 5.

As shown in the Figure, both HBsAg alone and HBsAg/HIVenv/V3 elicited a strong anti-HBsAg CTL response. Furthermore, while HIVenv/V3 peptide alone (composition (b)) elicited no specific CTL response, a strong anti-HIVenv/V3 CTL response was seen for the peptide delivered
10 in HBsAg (composition (c)).

These results show that proteins and peptides can be delivered to antigen-presenting cells (APC) *in vivo* by HBsAg particles for processing and immunogenic presentation via the Class I pathway, thus stimulating CTL precursors. This CTL response is elicited even for antigens that are not immunogenic for CTL when injected as native proteins.

15 In a related embodiment of this method, codelivery of antigen and cytokine in HBsAg can be employed to modulate the type of immune response primed or enhanced by a HBsAg/antigen formulation. For example, IL-12 drives CD4+ T-cell response polarization towards the Th1 phenotype and suppresses the Th2 phenotype. In contrast, IL-10 suppresses Th1-type response and enhances Th2-type response. Such compositions are useful when it is desired to modulate the
20 pathogenic phenotype of an autoimmune or allergic T-cell response. For example, in treatment of autoimmune disease, it is often desirable to shift the phenotype of the immune response, rather than suppressing the response entirely.

III. Modulation of CTL Response by Immunostimulants Encapsulated in HBsAg Particles

25 HBsAg particles, without adjuvants, induce a CTL response in H-2^d/L^{d+} (BALB/c, C.B-17) mice. Other strains of mice, e.g. H-2^d/L^d (dm2) and H-2^b (C57BL/6) mice, however, were found to be nonresponders (Schirmbeck *et al.*). It has been found, in accordance with the present invention, that encapsulation of immunostimulating molecules, e.g. cytokines, in HBsAg particles can induce a CTL response even in these 'nonresponder' strains.

30 HBsAg particles can also be used to deliver immunostimulatory oligonucleotides. Such a composition enhances the immunogenicity of the HBsAg for B cells (i.e., the antibody response) as well as T cells (CTL response). For example, oligonucleotides containing certain palindromic sequences were found to induce IFN and augment NK cell activity of mouse spleen cells (Yamamoto *et al.*, 1992, 1994). Other oligonucleotides have been effective as adjuvants in

inducing production of cytokines, activating B cells, monocytes, dendritic cells, and NK cells (Weiner; Wooldridge).

To produce the data shown in Figure 6, several cytokines were loaded into HBsAg particles, following a protocol such as outlined above for OVA, with incubation carried out at 45°C. It was
 5 estimated that approximately 10 ng of cytokine was incorporated per µg of HBsAg particles (about 1% incorporation) at this temperature. Groups of 'nonresponder' mice (H-2^b C57BL/6) were immunized with HBsAg particles, with and without incorporated cytokines, or with cytokine alone (Fig. 6G), in the amounts shown below:

- 10 A: 1 µg 'naked' HBsAg particles
- B-F: 1 µg HBsAg/cytokine, where the cytokine was:
 - (b) IL-12, (c) IFN-γ, (d) IL-2, (e) IL-4,
 - (f) IL-1 β peptide
- G: 1 µg IL-12 (control)
- 15 H: 1 µg HBsAg/IL-12

After 12 days, splenocytes from the immunized mice were restimulated in vitro for 5 days with HBsAg-pulsed, syngeneic irradiated RBL5 lymphoma cells. For control experiment H, the splenocytes were restimulated with non-pulsed, syngeneic RBL5 cells. The splenocytes (effector
 20 cells) were then cocultured with ⁵¹Cr-labeled target cells, and the CTL response was measured by a standard ⁵¹Cr release assay. The target cells were either non-pulsed EL4 cells (open circles in Figs. 6A-G), or EL4 cells which had been pulsed with HBsAg (solid circles).

Results are shown in Figs. 6A-H. In the control experiments (A and G), where the "nonresponder" mice were immunized with HBsAg alone or IL-12 alone, no CTL response was
 25 seen in the HBsAg-specific cells as compared to the control cells. Nor was any response seen in experiment H, in which the splenocytes were restimulated with non-antigen-bearing RBL5 cells.

Compositions D-F showed a similar lack of response. The lack of response from HBsAg encapsulating IL-4 (E) is not unexpected, as this cytokine is known to suppress the CTL response (see, for example, Nguyen, Geissler).

30 A strong CTL response was seen, however, for compositions B and C, where the cytokines were IL-12 and IFN-γ, respectively. This data shows that encapsulation of certain cytokines in HBsAg particles can induce a CTL response even in "nonresponder" strains; i.e., in subjects which do not show a CTL response to HBsAg alone.

In further experiments, the immunostimulating proteins cholera toxin (CT) and staphylococcal
 35 enterotoxin B (SEB), known as adjuvants for stimulation of CTL and humoral immune responses, were each incorporated into HBsAg particles, at a level of about 5-20 ng protein per µg HBsAg.

Preliminary experiments testing the immunogenicity of these compositions showed a striking enhancement of the CTL and antibody responses of the HBsAg particles.

IV. Incorporation of Glycolipids into the Outer Surface of HBsAg Particles

5 Glycolipids can be introduced into the HBsAg particle exterior membrane by lipid exchange, using either micelles or liposomes, as described in Felgner. In Felgner, co-incubation of ganglioside micelles (containing predominantly trisialoganglioside GT1b) with fused phosphatidyl choline vesicles, about 70 nm in diameter, or SUV, about 20 nm in diameter, resulted in incorporation of ganglioside on the outer surface of the vesicles. Alternatively, the glycolipids can
10 be introduced by the use of a glycolipid exchange protein, as described in Wong *et al.*

By such inclusion of glycolipids, particularly glycolipids containing available mannose residues, the particles may be targeted to specific antigen presenting cells, such as dendritic cells or macrophages. See, for example, Yachi, where modification of the surface of liposomes with fatty acid esters of mannobiose was found useful in targeting the liposomes to Kupffer cells and
15 other macrophages. Perin *et al.* have employed an acylated poly-(1,3)-galactoside for the targeting of macrophages.

The surface glycolipids of mycobacteria have been well characterized (see e.g. Aspinall, Puzo). These glycolipids, which are often species-specific, have been used for the identification of various species, such as *M. leprae* and *M. tuberculosis*, and for monitoring treatment of disease
20 caused by these organisms. In accordance with the present invention, HBsAg having a specific glycolipid incorporated into the lipid monolayer may be administered to induce a CTL response against mycobacteria-infected, syngeneic cells.

V. Administration

25 For use in humans, a preferred dose of encapsulated antigen is in the range of 0.01 to 20 µg, more preferably 0.02 to 2 µg, incorporated at about a 1 to 10 weight percent level in HBsAg particles. When HBsAg itself is the antigen, a preferred dose is in the 0.1 to 10 µg range, with about 1 to 10 weight percent of incorporated immunostimulant (e.g. cytokine). Administration may be by injection, e.g., intraperitoneal (ip), subcutaneous (sc), intravenous (iv), or
30 intramuscular (im).

While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications may be made without departing from the invention.

IT IS CLAIMED:

1. A method of stimulating or modulating an immune response to an antigenic molecule in a mammalian subject, comprising administering to said subject an effective amount of a composition comprising the antigenic molecule contained in an HBsAg particle.
2. The method of claim 1, wherein said immune response is a CTL response.
3. The method of claim 2, wherein said CTL response is enhanced relative to that produced by the antigenic molecule alone.
4. The method of claim 2, wherein said antigenic molecule, when administered without said HBsAg particle, is substantially ineffective in producing a CTL response in said subject.
5. The method of claim 1, wherein said HBsAg particle is a recombinant HBsAg particle derived from a mammalian cell.
6. The method of claim 1, wherein said molecule is an antigenic protein or peptide.
7. The method of claim 10, wherein said molecule is HIVenv/V3 peptide.
8. The method of claim 1, wherein said composition further comprises an immunostimulating molecule contained in said HBsAg particle.
9. The method of claim 8, wherein said immunostimulating molecule is a cytokine.
10. The method of claim 8, wherein said immunostimulating molecule is an oligonucleotide.
11. A method of stimulating or modulating an immune response to HBsAg in a mammalian subject, comprising administering to said subject an effective amount of a composition comprising an immunostimulating molecule contained in an HBsAg particle.
12. The method of claim 11, wherein said immune response is a CTL response.
13. The method of claim 12, wherein said subject is a nonresponder at the CTL level when administered HBsAg particles without said immunostimulating molecule.

14. The method of claim 11, wherein said immunostimulating molecule is a cytokine.
15. The method of claim 11, wherein said immunostimulating molecule is cholera toxin (CT) protein or staphylococcal enterotoxin B (SEB) protein.
- 5 16. The method of claim 11, wherein said immunostimulating molecule is an oligonucleotide.
- 10 17. A composition comprising an HBsAg particle and, contained therein, a biologically active molecule.
18. The composition of claim 17, wherein said molecule is an antigen.
19. The composition of claim 18, wherein said molecule is HIVenv/K^d peptide.
- 15 20. The composition of claim 17, further comprising an immunostimulating molecule contained in said HBsAg particle.
21. The composition of claim 17, wherein said biologically active molecule is an immunostimulating molecule.
- 20 22. The composition of claim 21, wherein said immunostimulating molecule is a cytokine.
23. The composition of claim 21, wherein said immunostimulating molecule is an oligonucleotide.
- 25 24. The composition of claim 21, wherein said immunostimulating molecule is cholera toxin (CT) protein or staphylococcal enterotoxin B (SEB) protein.
- 30 25. The composition of claim 17, further comprising a glycolipid incorporated into the exterior surface of the lipid bilayer of said HBsAg particle.
26. The composition of claim 17, wherein said composition is prepared by incubating said particle in an aqueous medium in the presence of said molecule.
- 35 27. A method of incorporating a biologically active molecule into an HBsAg particle, comprising incubating said particle in an aqueous medium in the presence of said molecule.

28. The method of claim 27, wherein the temperature of said incubating is between about 35°C and about 60°C.

29. The method of claim 27, further comprising incorporating a glycolipid into the exterior
5 surface of said HBsAg particle.

30. The method of claim 29, wherein said incorporating comprises co-incubating said glycolipid with said HBsAg particles and said biologically active molecule.

ABSTRACT

Compositions of HBsAg particles having biologically active molecules contained in the particles, and methods of their use, e.g. in stimulating enhanced immune responses, are described.

Antigenic peptides contained in HBsAg particles were found to produce a CTL response where
5 none was elicited by the peptide alone. Encapsulation of immunostimulating molecules, such as cytokines, greatly enhanced the CTL response evoked by the HBsAg particles themselves.




Fig. 1A

Fig. 1B




Fig. 2A




Fig. 2B




Fig. 4A




Fig. 4B




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 5A




Fig. 5B




Fig. 6B




Fig. 6C



Fig. 6D




Fig. 6E




Fig. 6F



Fig. 6G



Fig. 6H



Fig. 6I

INVENTORSHIP DECLARATION BY JOINT INVENTORS

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are stated next to my name in PART A on hereof.

I believe I am the original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

Delivery of Immunogenic Molecules via HbsAg Particles

the specification of which:

- is attached hereto.
- was filed on _____ as Application Serial No. _____ and
was amended on _____ (if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed in PART B hereof and have also identified in PART B on hereof any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed.

I hereby claim the benefit under Title 35, United States Code §119(e) and §120, of any United States application(s) listed in PART C hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56 which occurred between the filing date of the prior application and any national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please direct all telephone calls to LeeAnn Gorthey, Ph.D. at (650) 324-0880. Address all correspondence to:

**Dehlinger & Associates
P.O. Box 60850
Palo Alto, CA 94306-0850**

INVENTORSHIP DECLARATION BY JOINT INVENTORS**PART A: INVENTOR INFORMATION AND SIGNATURE**Full name of FIRST inventor: Jörg ReimannCitizenship:German Post Office Address: Institut für Medizinische
Mikrobiologie, Universität
Ulm, D-89081, Germany

Residence (if different): _____

Inventor's Signature: _____ Date: _____

Full name of SECOND inventor: Yechezkel BarenholzCitizenship:Israeli Post Office Address: 18 Nave Shanan,
Jerusalem 93707, Israel

Residence (if different): _____

Inventor's Signature: _____ Date: _____

* * * * *

PART B: CLAIM TO PRIORITY OF FOREIGN APPLICATION(S) UNDER 35 U.S.C. 119(a-d)Country App. No. Filing Date**PART C: CLAIM TO PRIORITY OF U.S. PROVISIONAL AND NONPROVISIONAL
APPLICATION(S) UNDER 35 U.S.C. 119(e) AND 120**

<u>Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
60/073,476	02/03/98	<input type="checkbox"/> Patented <input checked="" type="checkbox"/> Pending <input type="checkbox"/> Abandoned <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned